Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Price Target at $42.70

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has been given an average rating of “Moderate Buy” by the eleven brokerages that are presently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $42.70.

ARWR has been the topic of several research reports. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday. Piper Sandler lowered their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. Sanford C. Bernstein cut their price target on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a report on Friday, November 29th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, September 9th. Finally, StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, Director William D. Waddill sold 3,748 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $21.90, for a total value of $82,081.20. Following the completion of the transaction, the director now directly owns 44,125 shares in the company, valued at approximately $966,337.50. This represents a 7.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Richard Anzalone sold 26,712 shares of the stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $21.24, for a total value of $567,362.88. Following the transaction, the chief executive officer now owns 3,688,335 shares in the company, valued at $78,340,235.40. This trade represents a 0.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 43,023 shares of company stock valued at $895,553. 4.50% of the stock is owned by corporate insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Fifth Third Bancorp lifted its holdings in shares of Arrowhead Pharmaceuticals by 42.5% in the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 354 shares during the last quarter. World Investment Advisors LLC lifted its stake in Arrowhead Pharmaceuticals by 3.8% in the third quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock worth $371,000 after purchasing an additional 700 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Arrowhead Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 788 shares during the period. Arizona State Retirement System grew its stake in shares of Arrowhead Pharmaceuticals by 2.4% during the second quarter. Arizona State Retirement System now owns 34,685 shares of the biotechnology company’s stock valued at $901,000 after buying an additional 821 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Arrowhead Pharmaceuticals by 1.5% in the third quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company’s stock worth $1,199,000 after buying an additional 886 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Up 1.5 %

Shares of Arrowhead Pharmaceuticals stock opened at $19.75 on Tuesday. The stock has a market capitalization of $2.46 billion, a P/E ratio of -3.93 and a beta of 0.91. Arrowhead Pharmaceuticals has a 52-week low of $17.05 and a 52-week high of $39.83. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74. The stock’s 50-day simple moving average is $21.26 and its 200 day simple moving average is $22.99.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.